KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Investment Securities (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Gains from Investment Securities data on record, last reported at $3.6 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 92.91% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $8.8 million, down 93.14%, while the annual FY2025 figure was $8.8 million, 2556.36% up from the prior year.
  • Gains from Investment Securities reached $3.6 million in Q4 2025 per SRPT's latest filing, up from -$14.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $80.5 million in Q4 2023 and bottomed at -$76.2 million in Q3 2023.
  • Average Gains from Investment Securities over 5 years is $2.8 million, with a median of $535000.0 recorded in 2023.
  • The widest YoY moves for Gains from Investment Securities: up 18761011.11% in 2022, down 17157.14% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at $77000.0 in 2021, then crashed by 17157.14% to -$13.1 million in 2022, then soared by 713.12% to $80.5 million in 2023, then tumbled by 37.17% to $50.6 million in 2024, then tumbled by 92.91% to $3.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $3.6 million in Q4 2025, -$14.9 million in Q3 2025, and $14.9 million in Q2 2025.